263 related articles for article (PubMed ID: 24057925)
61. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
62. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
63. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
64. [Splenic marginal zone lymphoma].
Dimopoulos K; Pedersen M
Ugeskr Laeger; 2012 Oct; 174(40):2383-6. PubMed ID: 23031300
[TBL] [Abstract][Full Text] [Related]
65. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
66. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
[TBL] [Abstract][Full Text] [Related]
67. Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival.
Yang Z; Liu L; Leng K; Shi G
Ann Surg Oncol; 2023 Nov; 30(12):7206-7216. PubMed ID: 37516724
[TBL] [Abstract][Full Text] [Related]
68. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
Pohlen M; Gerth HU; Liersch R; Koschmieder S; Mesters RM; Kessler T; Appelmann I; Müller-Tidow C; Berdel WE
Am J Hematol; 2011 Dec; 86(12):E61-4. PubMed ID: 21898532
[TBL] [Abstract][Full Text] [Related]
69. [Splenic marginal zone B-cell lymphoma with bilateral renal invasion after splenectomy].
Hoshino T; Iriuchijima H; Ogawa Y; Irisawa H; Jinbo T
Rinsho Ketsueki; 2008 Jan; 49(1):35-9. PubMed ID: 18277594
[TBL] [Abstract][Full Text] [Related]
70. Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
Sima A; Hollander P; Baecklund E; Smedby KE; Enblad G; Amini RM
Br J Haematol; 2021 Aug; 194(3):568-579. PubMed ID: 34109612
[TBL] [Abstract][Full Text] [Related]
71. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Dimopoulou MN; Vassilakopoulos TP; Kyrtsonis MC; Korkolopoulou P; Kontopidou FN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Tsaftaridis P; Plata E; Angelopoulou MK
Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
[TBL] [Abstract][Full Text] [Related]
72. Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma.
Vlădăreanu AM; Onisâi M; Ciufu C; Bumbea H; Cîşleanu D; Voican I; Nicolescu A; Radeşi S; Vintilescu A; Băluţă C; Dobrea C; Savlovschi C; Grecu L; Serban D; Serafim G
Rom J Intern Med; 2009; 47(2):191-9. PubMed ID: 20067170
[TBL] [Abstract][Full Text] [Related]
73. Non-MALT marginal zone lymphomas.
Thieblemont C
Ann Oncol; 2008 Jun; 19 Suppl 4():iv70-3. PubMed ID: 18519410
[No Abstract] [Full Text] [Related]
74. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
Kang HJ; Kim WS; Kim SJ; Lee JJ; Yang DH; Kim JS; Lee SR; Lee GW; Kim HJ; Kim HY; Oh SY; Kim HC; Eom HS; Chung J; Park J; Suh C; Ryoo BY
Ann Hematol; 2012 Apr; 91(4):543-51. PubMed ID: 21922208
[TBL] [Abstract][Full Text] [Related]
75. Treatment of splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
[TBL] [Abstract][Full Text] [Related]
76. Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.
Komeno Y; Shibuya N; Uryu H; Yamada H; Toda T; Shibasaki M; Kunishima S; Iihara K; Ryu T
Intern Med; 2017; 56(5):557-562. PubMed ID: 28250305
[TBL] [Abstract][Full Text] [Related]
77. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
[TBL] [Abstract][Full Text] [Related]
78. Splenic marginal zone lymphoma: A US population-based survival analysis (1999-2016).
Florindez JA; Alderuccio JP; Reis IM; Lossos IS
Cancer; 2020 Nov; 126(21):4706-4716. PubMed ID: 32767702
[TBL] [Abstract][Full Text] [Related]
79. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
80. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation.
Hoehn D; Miranda RN; Kanagal-Shamanna R; Lin P; Medeiros LJ
Hum Pathol; 2012 Nov; 43(11):1828-38. PubMed ID: 22520947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
